Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

FGEN

FibroGen (FGEN)

FibroGen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FGEN
DateTimeSourceHeadlineSymbolCompany
08/05/202401:55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202421:00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
07/05/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
07/05/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
07/05/202406:02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202421:00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
25/04/202406:02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
03/04/202408:46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202422:00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202422:00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
09/03/202411:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
09/03/202411:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
09/03/202411:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
27/02/202408:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
27/02/202408:06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
27/02/202408:05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
24/02/202412:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
24/02/202412:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
24/02/202412:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
20/02/202423:00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
15/02/202407:37Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
06/02/202412:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
05/02/202423:00GlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
25/01/202423:00GlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
27/12/202311:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/12/202308:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/12/202308:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
12/12/202308:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
10/12/202309:02GlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
07/11/202308:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
 Showing the most relevant articles for your search:NASDAQ:FGEN